Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/28/2026

1. SPY
2. CDNS
3. NVDA
4. AAPL
5. USO
6. META
7. FFIV
8. TFII
9. XFLT
10. AMZN

Go back to Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
(NASDAQ: DARE) Delayed: 1.19 -0.13 (9.85%)
Previous Close $1.32    52 Week High $ 
Open $1.31    52 Week Low $ 
Day High $1.31    P/E N/A 
Day Low $1.18    EPS $ 
Volume 169,480